Capivasertib with abiraterone acetate is in clinical development for the treatment of prostate cancer which is metastatic (has spread to other parts of the body) and hormone-sensitive, meaning the cancer can be controlled by keeping the testosterone level as low as would be expected if the testicles were removed. Specifically, capivasertib with abiraterone acetate is indicated for patients who have phosphatase and tensin homolog (PTEN) deficiency, meaning the PTEN gene (a tumour suppressor gene) has been deleted. PTEN deficiency is associated with advanced prostate cancer development and poor clinical outcomes. Symptoms of advanced prostate cancer can include a frequent need to urinate, straining while urinating, and blood in urine or semen Metastatic prostate cancer is considered incurable. There is therefore a need to develop new treatment options for this population.
Capivasertib with abiraterone acetate for treating metastatic PTEN deficient hormone-sensitive prostate cancer
Capivasertib with abiraterone acetate is in clinical development for the treatment of prostate cancer which is metastatic (has spread to other parts of the body) and hormone-sensitive, meaning the cancer can be controlled by keeping the testosterone level as low as would be expected if the testicles were removed.